Bayer rules out expensive acquisitions to focus on academia
This article was originally published in Scrip
Executive Summary
Bayer is adamant that it will avoid billion-dollar transactions in healthcare this year and has no interest in buying a generics business. Instead it will focus on developing external links with research institutions such as universities, says board chairman Werner Wenning.